Natco Pharma Overview
- Year Founded
-
1981
- Status
-
Public
- Employees
-
5,060
- Stock Symbol
-
524816
- Investments
-
15
- Share Price
-
$8.64
- (As of Friday Closing)
Natco Pharma General Information
Description
Natco Pharma Ltd is engaged in the development, manufacturing, and marketing of Finished Dosage Formulations (FDFs), Active Pharmaceutical Ingredients (APIs), and Agrochemicals. The Group's API business develops cGMP-compliant drug substances, with oncology as its core therapeutic area, along with CNS, pain management, and cardiovascular care. The FDFs portfolio comprises products across neurology, oncology, hepatology, infectious diseases, cardiology, and other areas, and the Agrochemicals business offers insecticides, fungicides, plant growth promoters, herbicides, and other related products. Its reportable segments are Pharmaceuticals, which derives key revenue, and Agro Chemicals. Geographically, the Group derives maximum revenue from the USA, and the rest from India and other markets.
Contact Information
Website
www.natcopharma.co.inCorporate Office
- Natco House
- Road Number 2, Banjara Hills
- Hyderabad, Andhra Pradesh 500034
- India
Corporate Office
- Natco House
- Road Number 2, Banjara Hills
- Hyderabad, Andhra Pradesh 500034
- India
Natco Pharma Stock Performance
As of 13-Nov-2026, Natco Pharma’s stock price is $8.64. Its current market cap is $1.69B with 196M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.64 | $8.63 | $8.14 - $12.81 | $1.69B | 196M | 43.8K | $0.49 |
Natco Pharma Financials Summary
As of 30-Sep-2026, Natco Pharma has a trailing 12-month revenue of $333M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 1,472,649 | 1,440,302 | 1,404,917 | 1,928,160 |
| Revenue | 333,146 | 457,710 | 521,730 | 480,614 |
| EBITDA | 105,469 | 168,814 | 278,675 | 213,962 |
| Net Income | 89,356 | 160,530 | 222,973 | 167,698 |
| Total Assets | 1,228,387 | 1,173,651 | 1,008,987 | 828,158 |
| Total Debt | 107,588 | 75,663 | 32,663 | 44,512 |
Natco Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Natco Pharma Comparisons
Industry
Financing
Details
Natco Pharma Competitors (12)
One of Natco Pharma’s 12 competitors is Gland Pharma, a Formerly PE-Backed company based in Hyderabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gland Pharma | Formerly PE-Backed | Hyderabad, India | ||||
| Neuland Laboratories | Corporation | Hyderabad, India | ||||
| Maiva Pharma | Private Equity-Backed | Krishnagiri, India | ||||
| Zydus Lifesciences | Corporation | Ahmedabad, India | ||||
| Cipla | Corporation | Mumbai, India |
Natco Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Natco Pharma Patents
Natco Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026196308-A1 | A process for the preparation of olaparib and purification thereof | Pending | 19-Mar-2025 | ||
| WO-2026094064-A1 | Process for the synthesis of intermediate compounds useful for the preparation of galnac (l96) conjugated oligonucleotides | Pending | 30-Oct-2024 | ||
| WO-2025257846-A1 | An improved process for the preparation of belumosudil mesylate and its intermediates thereof | Pending | 14-Jun-2024 | ||
| WO-2025173029-A1 | An improved process for the preparation of deucravacitinib | Pending | 14-Feb-2024 | ||
| AU-2024408729-A1 | Biphenyl pyridine rigid compounds with polycyclic heterocycles useful as dual immune checkpoint inhibitors | Active | 22-Dec-2023 | A61P35/00 |
Natco Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Natco Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Natco Pharma Investments & Acquisitions (15)
Natco Pharma’s most recent deal was a Later Stage VC with Egenesis. The deal was made on 29-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Egenesis | 29-Sep-2026 | Later Stage VC | Drug Discovery | ||
| Pee Safe | 14-Jan-2026 | Later Stage VC | Personal Products | ||
| Egenesis | 04-Sep-2024 | Later Stage VC | Drug Discovery | ||
| Cellogen Therapeutics | 17-Jan-2024 | Corporate | Biotechnology | ||
| Zista Pharma | 31-Dec-2023 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Natco Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.56 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Natco Pharma Exits (1)
Natco Pharma’s most recent exit was on 12-Jul-2007 from SaveMart Pharmacy. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| SaveMart Pharmacy | 12-Jul-2007 | Completed |
|
Natco Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| K & C Pharmacy | Lorton, VA |
Natco Pharma FAQs
-
When was Natco Pharma founded?
Natco Pharma was founded in 1981.
-
Where is Natco Pharma headquartered?
Natco Pharma is headquartered in Hyderabad, India.
-
What is the size of Natco Pharma?
Natco Pharma has 5,060 total employees.
-
What industry is Natco Pharma in?
Natco Pharma’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Natco Pharma a private or public company?
Natco Pharma is a Public company.
-
What is Natco Pharma’s stock symbol?
The ticker symbol for Natco Pharma is 524816.
-
What is the current stock price of Natco Pharma?
As of 13-Nov-2026 the stock price of Natco Pharma is $8.64.
-
What is the current market cap of Natco Pharma?
The current market capitalization of Natco Pharma is $1.69B.
-
What is Natco Pharma’s current revenue?
The trailing twelve month revenue for Natco Pharma is $333M.
-
Who are Natco Pharma’s competitors?
Gland Pharma, Neuland Laboratories, Maiva Pharma, Zydus Lifesciences, and Cipla are some of the 12 competitors of Natco Pharma.
-
What is Natco Pharma’s annual earnings per share (EPS)?
Natco Pharma’s EPS for 12 months was $0.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
